Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Loratadine exclusivity

This article was originally published in The Tan Sheet

Executive Summary

Andrx "will accept Wyeth's offer to forsake generic exclusivity" after Aug. 9 and requests FDA adopt "appropriate measures to implement Wyeth's offer" in March 21 comments. In a recent citizen petition, Andrx alleged marketing exclusivity for Wyeth's generic loratadine should start from the Alavert approval date, although Wyeth disputed the assertion (1"The Tan Sheet" March 31, 2003, p. 9). While Andrx accepts Wyeth's "compromise," firm maintains Wyeth's position "cannot be right," because firm "implicitly concedes as much by offering to forsake generic exclusivity 180 days after a date that is before the date on which it will commence" marketing of generic loratadine...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS095318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel